Inclusion Criteria:

• Patient must be willing to give written informed consent, make the required study visits, and follow instructions.
• Patient must be 55 years of age or older.
• Patient must state the ability to administer eye drops or have a caretaker to administer the eye drops.

• The study eye must have:

  • A well-demarcated area of atrophy secondary to age-related macular degeneration
  • If the lesion is multifocal, at least one focal lesion must be equal to or larger than 1.25 mm2 [0.5 Disc Areas (DA)]
  • The total lesion size must be less than or equal to 20 mm2 [8 (DA)].
• Presence of hyperautofluorescence adjacent to an area of atrophy.
• No evidence of CNV
• A best corrected visual acuity (BCVA) of 35 letters (20/200 Snellen equivalent) or better.
• Clear ocular media and adequate pupillary dilation to permit good quality photographic imaging.
• There are no inclusion criteria for the fellow eye.

Exclusion Criteria:

• Pregnant or nursing (lactating) women.
• Pre-menopausal women of child-bearing potential not using adequate contraception.
• Ocular disease in the study eye that in the opinion of the Investigator may confound assessment of the retina or affect central vision, other than non-exudative AMD [e.g., branch retinal vein occlusion (BCVO), diabetic retinopathy, uveitis].
• History of cataract surgery in either eye within the past three (3) months of screening (Visit 1).
• History or evidence of serious ocular trauma or intraocular surgery (e.g. Lasik, keratoplasty) in either eye within the past six (6) months of screening (Visit 1).
• Evidence of significant uncontrolled comorbidity or condition with a limited survival prognosis (e.g., cancer, severe/unstable cardiovascular disease) that would make participation in the trial or adherence to the study schedule difficult or unlikely.
• Participation in an investigational drug or device study within 30 days of screening (Visit 1).